{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:00:22Z","timestamp":1791165622031,"version":"4.1.0"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anthracyclines, potent chemotherapeutic agents derived from Streptomyces species, play a pivotal role in the treatment of various malignancies, particularly haematologic and solid tumors in humans. Despite their efficacy, their clinical utility is hampered by dose-dependent, irreversible chronic cardiotoxicity, which contributes to rising morbidity and mortality among cancer survivors. This is a limitation and drawback of anthracycline drugs, which constrain their therapeutic potency, clinical effectiveness, pharmacological activity and therapeutic impact. Compromised pharmacodynamic efficacy compromises patient safety and poses significant obstacles to achieving remission, thereby affecting patient tolerability and increasing risk. Type-1 anthracycline-induced cardiotoxicity (AIC) involves progressive cardiomyocyte loss and heart failure, presenting a serious challenge in cardio-oncology. Recent advances have elucidated molecular mechanisms underpinning AIC, including topoisomerase II inhibition, oxidative stress (reactive oxygen species generation), and mitochondrial dysfunction, enabling targeted research and precision-based interventions. It elucidates advanced translational toxicology by enabling mitochondrial-targeted drug-induced cardiotoxicity, resulting in mitochondrial dysfunction offering precision-based cardiac function studies and optimising patient-specific clinical outcomes as study results. Using cardiac magnetic resonance and magnetic resonance spectroscopy (MRS) imaging techniques, the study further highlighted how advancements in emerging technology play a pivotal role in cardiac function studies. Over and above that, a detailed dissection with a thorough examination of the heart and its muscles through autopsy and histological analysis of cardiac tissue under the microscope revealed significant, substantial histopathological evidence, confirming the cardiotoxic effects. Anthracycline-associated cardiac complications with other agents encompass concerns such as: bradycardia, tachyarrhythmias, blocks in the heart\u2019s electrical signals, reduced blood flow to the heart muscle (myocardial ischaemia) and frequent hypotension.<\/jats:p>","DOI":"10.1093\/toxres\/tfaf184","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:11:17Z","timestamp":1765458677000},"source":"Crossref","is-referenced-by-count":4,"title":["A toxicological report on drug-induced toxicity evaluation: integrated preclinical findings from in vitro and in vivo studies to human risk prediction and lethal outcomes, including teratogenic effects and mortality"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3138-2809","authenticated-orcid":false,"given":"Saurabh Dilip","family":"Bhandare","sequence":"first","affiliation":[{"name":"Foxabell - Laboratorium Investigativum, Laboratorium Scientiae et Studiorum Investigativorum , Research Nashik, Maharashtra 422101 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026012907423499500_ref1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/3-540-29804-5_40","volume-title":"Drug discovery and evaluation: safety and pharmacokinetics assays","author":"Mayer","year":"2006"},{"key":"2026012907423499500_ref2","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.15829\/1560-4071-2021-4703","article-title":"Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian","volume":"26","author":"Vasyuk","year":"2021","journal-title":"J Cardiol"},{"key":"2026012907423499500_ref3","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.15829\/1560-4071-2024-6162","article-title":"2024 clinical practice guidelines for chronic heart failure","volume":"29","author":"Galyavich","year":"2024","journal-title":"Russian J Cardiol"},{"key":"2026012907423499500_ref4","doi-asserted-by":"publisher","first-page":"101336","DOI":"10.1016\/j.ijcha.2024.101336","article-title":"A single-lead ECG based cardiotoxicity detection in patients on polychemotherapy","volume":"50","author":"Mesitskaya","year":"2024","journal-title":"IJC Heart Vasc"},{"key":"2026012907423499500_ref5","first-page":"2514","article-title":"Treatment of covid-19 by studying and observing prescription-based medication in a patient reported with covid, sars-cov case, an actual practice in pharmacy and, the hospitals. A case study report","volume":"11","author":"Bhandare","year":"2022","journal-title":"World J Pharma Res"},{"key":"2026012907423499500_ref6","first-page":"1854","article-title":"A scientific analysis report on the extensive research of anti-cancer medications and, its comprehensive studies","volume":"11","author":"Bhandare","year":"2022","journal-title":"World J Pharma Res"},{"key":"2026012907423499500_ref7","first-page":"2175","article-title":"Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer","volume":"22","author":"Nicolazzi","year":"2018","journal-title":"PubMed."},{"key":"2026012907423499500_ref8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00392-019-01448-4","article-title":"Cardioprotective effect of renin\u2013angiotensin inhibitors and \u03b2-blockers in trastuzumab-related cardiotoxicity","volume":"108","author":"Ohtani","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2026012907423499500_ref9","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2026012907423499500_ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15275\/rusomj.2020.0305","article-title":"Pathophysiological mechanisms of cardiotoxicity in chemotherapeutic agents","volume":"9","author":"Chaulin","year":"2020","journal-title":"Russian Open Med J"},{"key":"2026012907423499500_ref11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cpt.2024.04.004","article-title":"Cardiotoxicity in platinum-based chemotherapy: mechanisms, manifestations, and management","volume":"3","author":"Rachma","year":"2024","journal-title":"CPT"},{"key":"2026012907423499500_ref12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jaccao.2025.01.005","article-title":"Empagliflozin to prevent doxorubicin cardiotoxicity","volume":"7","author":"Guo","year":"2025","journal-title":"JACC CardioOncology"},{"key":"2026012907423499500_ref13","volume-title":"Drug induced cardiotoxicity: mechanism, prevention and management","author":"Kelleni","year":"2018"},{"key":"2026012907423499500_ref14","doi-asserted-by":"publisher","first-page":"e000687","DOI":"10.1136\/openhrt-2017-000687","article-title":"Effectiveness of pharmacist's intervention in the management of cardiovascular diseases","volume":"5","author":"Omboni","year":"2018","journal-title":"Open Heart"},{"key":"2026012907423499500_ref15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"2026012907423499500_ref16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2015.09.025","article-title":"The role of the clinical pharmacist in the care of patients with cardiovascular disease","volume":"66","author":"Dunn","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012907423499500_ref17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.repce.2012.11.019","article-title":"Cardiotoxicity associated with cancer therapy: pathophysiology and prevention","volume":"32","author":"Ad\u00e3o","year":"2013","journal-title":"Revista Portuguesa De Cardiologia (English Edition)"},{"key":"2026012907423499500_ref18","first-page":"75","article-title":"Chemotherapy and cardiotoxicity","volume":"9","author":"Broder","year":"2008","journal-title":"Rev Cardiovasc Med"},{"key":"2026012907423499500_ref19","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/mjt.0000000000001428","article-title":"Dose-dependent 5-fluorouracil\u2013associated coronary artery spasm","volume":"29","author":"Ko","year":"2022","journal-title":"Am J Ther"},{"key":"2026012907423499500_ref20","doi-asserted-by":"publisher","first-page":"219.1","DOI":"10.1136\/hrt.86.2.219","article-title":"Docetaxel induced cardiotoxicity","volume":"86","author":"Shimoyama","year":"2001","journal-title":"Heart."},{"key":"2026012907423499500_ref21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/FJC.0000000000001344","article-title":"Cardiac safety of imatinib for the treatment of COVID-19: a secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Duijvelaar","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012907423499500_ref22","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.6004\/jnccn.2020.5004","article-title":"Cardiovascular health and risk management in cancer survivors","volume":"18","author":"Moslehi","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"2026012907423499500_ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2967142","article-title":"Mulberrin confers protection against doxorubicin-induced cardiotoxicity via regulating AKT Signaling pathways in mice","volume":"2022","author":"Ye","year":"2022","journal-title":"Oxidative Med Cell Longev"},{"key":"2026012907423499500_ref24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","article-title":"Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study","volume":"147","author":"Foulkes","year":"2023","journal-title":"Circulation."},{"key":"2026012907423499500_ref25","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/ehf2.14466","article-title":"Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial","volume":"10","author":"Tajstra","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012907423499500_ref26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/COC.0000000000001111","article-title":"Neuromodulation of cardiovascular risks associated with cardiotoxic chemotherapy: a first-in-human randomized pilot study. Neuromodulation in cancer study (NCAN)","volume":"47","author":"Nagai","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"2026012907423499500_ref27","doi-asserted-by":"publisher","first-page":"107630","DOI":"10.1016\/j.phrs.2025.107630","article-title":"Cardioprotective effect of crocin in patients with breast cancer receiving anthracycline-based chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"213","author":"Li","year":"2025","journal-title":"Pharmacol Res"},{"key":"2026012907423499500_ref28","doi-asserted-by":"publisher","first-page":"e039745","DOI":"10.1161\/JAHA.124.039745","article-title":"Randomized, placebo-controlled, triple-blind clinical trial of ivabradine for the prevention of cardiac dysfunction during anthracycline-based cancer therapy","volume":"14","author":"Rizk","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026012907423499500_ref29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaccao.2024.12.004","article-title":"SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics","volume":"7","author":"Medina-Hern\u00e1ndez","year":"2025","journal-title":"JACC Cardiooncology"},{"key":"2026012907423499500_ref30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1536\/ihj.24-293","article-title":"Subclinical B-type natriuretic peptide elevation 24 months after anthracycline-containing chemotherapy","volume":"66","author":"Tani","year":"2025","journal-title":"Int Heart J"},{"key":"2026012907423499500_ref31","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1007\/s11547-024-01897-6","article-title":"Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial","volume":"129","author":"Marrazzo","year":"2024","journal-title":"Radiol Med"},{"key":"2026012907423499500_ref32","volume-title":"CISPlatin injection","author":"FDA"},{"key":"2026012907423499500_ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2025.05.011","article-title":"Leonurine protects against cisplatin-induced ototoxicity through its anti-oxidation and anti-apoptosis properties","volume":"410","author":"Zeng","year":"2025","journal-title":"Toxicol Lett"},{"key":"2026012907423499500_ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000546204","article-title":"Statin and immune-related cardiovascular events in lung cancer patients receiving immune checkpoint inhibitors","author":"Song","year":"2025","journal-title":"Oncology."},{"key":"2026012907423499500_ref35","first-page":"415","volume-title":"Wilson and Gisvold\u2019s textbook of organic medicinal and pharmaceutical chemistry","author":"Block","year":"2004","edition":"11th"},{"key":"2026012907423499500_ref36","volume-title":"NCI dictionary of cancer terms"},{"key":"2026012907423499500_ref37","first-page":"1165","volume-title":"Foye\u2019s principles of medicinal chemistry","author":"Lemke","year":"2008","edition":"6th"},{"key":"2026012907423499500_ref38","first-page":"1191","volume-title":"Encyclopedia of pharmaceutical technology 3rd edition","author":"Swarbrick","year":"2007"},{"key":"2026012907423499500_ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","article-title":"Anthracyclines in the treatment of cancer","volume":"54","author":"Hortob\u00e1gyi","year":"1997","journal-title":"Drugs"},{"key":"2026012907423499500_ref40","volume-title":"Anthracycline toxicity","author":"Johnson","year":"2025"},{"key":"2026012907423499500_ref41","first-page":"34","article-title":"Lymphoma: diagnosis and treatment","volume":"101","author":"Lewis","year":"2020","journal-title":"Am Fam Physician"},{"key":"2026012907423499500_ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.02.014","article-title":"Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: design and rationale of the CARDIOTOX trial","volume":"285","author":"Da Silva Costa","year":"2025","journal-title":"Am Heart J"},{"key":"2026012907423499500_ref43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/10742484241304304","article-title":"Factors associated with the recovery of left ventricular ejection fraction in patients with anthracycline-induced left ventricular dysfunction","volume":"30","author":"Shugg","year":"2025","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012907423499500_ref44","doi-asserted-by":"publisher","first-page":"12759","DOI":"10.1038\/s41598-023-40061-4","article-title":"Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial","volume":"13","author":"Osataphan","year":"2023","journal-title":"Sci Rep"},{"key":"2026012907423499500_ref45","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaccao.2024.03.001","article-title":"(less) time and energy","volume":"6","author":"Kirkland","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026012907423499500_ref46","volume-title":"Ejection fraction heart failure measurement","year":"2025"},{"key":"2026012907423499500_ref47","volume-title":"Cancer.gov","author":"ABVD","year":"2009"},{"key":"2026012907423499500_ref48","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/jco.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026012907423499500_ref49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2003-05-1611","article-title":"Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial","volume":"103","author":"Maignan","year":"2003","journal-title":"Blood."},{"key":"2026012907423499500_ref50","doi-asserted-by":"publisher","first-page":"e30000","DOI":"10.1097\/MD.0000000000030000","article-title":"Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: a pilot study","volume":"101","author":"Li","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026012907423499500_ref51","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/10428194.2018.1519812","article-title":"R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma","volume":"60","author":"Messmer","year":"2019","journal-title":"Leukemia & Lymphoma\/Leukemia and Lymphoma"},{"key":"2026012907423499500_ref52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113480","article-title":"Anthracyclines as topoisomerase II poisons: from early studies to new perspectives","volume":"19","author":"Marinello","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026012907423499500_ref53","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and Beta-blocker therapy to prevent anthracycline cardiotoxicity: the cardiac CARE trial","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation."},{"key":"2026012907423499500_ref54","doi-asserted-by":"publisher","first-page":"116362","DOI":"10.1016\/j.taap.2022.116362","article-title":"Upcycling the anthracyclines: new mechanisms of action, toxicology, and pharmacology","volume":"459","author":"Bayles","year":"2023","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026012907423499500_ref55","doi-asserted-by":"publisher","first-page":"1179546819866445","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin Med Insights Cardiol"},{"key":"2026012907423499500_ref56","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2401022","article-title":"Cardiotoxicity as a possible side effect of statins","volume":"24","author":"Chaulin","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"2026012907423499500_ref57","volume-title":"StatPearls","author":"Iorga","year":"2025"},{"key":"2026012907423499500_ref58","volume-title":"Herceptin final labeling text","author":"FDA Genentech, Inc","year":"1998"},{"key":"2026012907423499500_ref59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaccao.2024.02.005","article-title":"Anthracycline cardiotoxicity induces progressive changes in myocardial metabolism and mitochondrial quality control","volume":"6","author":"D\u00edaz-Guerra","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026012907423499500_ref60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejcsup.2014.03.002","article-title":"Cardiovascular disease after cancer therapy","volume":"12","author":"Aleman","year":"2014","journal-title":"EJC Suppl"},{"key":"2026012907423499500_ref61","doi-asserted-by":"publisher","first-page":"103129","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol"},{"key":"2026012907423499500_ref62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s12032-024-02426-1","article-title":"Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial","volume":"41","author":"Kettana","year":"2024","journal-title":"Med Oncol"},{"key":"2026012907423499500_ref63","volume-title":"Immune checkpoint inhibitors","year":"2022"},{"key":"2026012907423499500_ref64","doi-asserted-by":"publisher","DOI":"10.54289\/JCRMH2300105","article-title":"Cardiotoxicity due to docetaxel rare but it exists: about a case and literature review","volume":"3","author":"Bendahou","year":"2023","journal-title":"J Case Rep Med Hist"},{"key":"2026012907423499500_ref65","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026012907423499500_ref66","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2004.08.015","article-title":"Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell Tumors: a Pediatric intergroup study\u2014Pediatric oncology group 9049 and Children's cancer group 8882","volume":"22","author":"Cushing","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026012907423499500_ref67","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.1993.11.1.96","article-title":"Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric oncology group study","volume":"11","author":"Douglass","year":"1993","journal-title":"J Clin Oncol"},{"key":"2026012907423499500_ref68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2131\/jts.14.115","article-title":"Teratogenic effects of carboplatin, an oncostatic drug, administered during the early organogenetic period in rats","volume":"14","author":"Kai","year":"1989","journal-title":"J Toxicol Sci"},{"key":"2026012907423499500_ref69","doi-asserted-by":"publisher","first-page":"263.e1","DOI":"10.1016\/j.ajog.2022.01.004","article-title":"Prenatal exposure to teratogenic medications in the era of risk evaluation and mitigation strategies","volume":"227","author":"Sarayani","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2026012907423499500_ref70","volume-title":"Highlights of prescribing information","author":"Ingenus Pharmaceuticals, LLC","year":"2020"},{"key":"2026012907423499500_ref71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0305-7372(85)90011-8","article-title":"Ifosfamide\u2013pharmacology, safety and therapeutic potential","volume":"12","author":"Brade","year":"1985","journal-title":"Cancer Treat Rev"},{"key":"2026012907423499500_ref72","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1158\/0008-5472.CAN-06-1043","article-title":"Ifosfamide-induced nephrotoxicity: mechanism and prevention","volume":"66","author":"Nissim","year":"2006","journal-title":"Cancer Res"},{"key":"2026012907423499500_ref73","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/ndt\/12.6.1091","article-title":"Nephrotoxicity of ifosfamide - moving towards understanding the molecular mechanisms","volume":"12","author":"Rossi","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2026012907423499500_ref74","doi-asserted-by":"publisher","first-page":"114003","DOI":"10.1016\/j.ejogrb.2025.114003","article-title":"Safety of ifosfamide during pregnancy: a comprehensive analysis","volume":"311","author":"Devant","year":"2025","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026012907423499500_ref75","author":"FDA IFOSFAMIDE injection","year":"1988"},{"key":"2026012907423499500_ref76","volume-title":"BUSULFEX","author":"Otsuka America Pharmaceutical, Inc","year":"1999"},{"key":"2026012907423499500_ref77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.32607\/actanaturae.11375","article-title":"Cardiovascular effects of snake toxins: cardiotoxicity and cardioprotection","volume":"13","author":"Averin","year":"2021","journal-title":"Acta Nat"},{"key":"2026012907423499500_ref78","doi-asserted-by":"publisher","first-page":"20231","DOI":"10.1038\/s41598-019-56643-0","article-title":"An in vivo examination of the differences between rapid cardiovascular collapse and prolonged hypotension induced by snake venom","volume":"9","author":"Kakumanu","year":"2019","journal-title":"Sci Rep"},{"key":"2026012907423499500_ref79","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jad.2025.01.042","article-title":"Quetiapine is associated with pancreatitis: a real-world pharmacovigilance study","volume":"374","author":"Frey","year":"2025","journal-title":"J Affect Disord"},{"key":"2026012907423499500_ref80","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1161\/CIRCULATIONAHA.124.070709","article-title":"Preventing allogeneic stem cell transplant-related cardiovascular dysfunction: ALLO-active trial","volume":"151","author":"Dillon","year":"2025","journal-title":"Circulation."},{"key":"2026012907423499500_ref81","doi-asserted-by":"publisher","first-page":"e14719","DOI":"10.1111\/psyp.14719","article-title":"Patterns of adaptation to stress cardiovascular responses in smokers during ad libitum smoking and withdrawal","volume":"62","author":"Keogh","year":"2025","journal-title":"Psychophysiology."},{"key":"2026012907423499500_ref82","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2174\/1570159X19666210211150856","article-title":"Use of phenytoin, phenobarbital carbamazepine, levetiracetam lamotrigine and valproate in pregnancy and breastfeeding: risk of major malformations, dose-dependency, monotherapy vs polytherapy, pharmacokinetics and clinical implications","volume":"19","author":"Kaplan","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"2026012907423499500_ref83","volume-title":"Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review","author":"Medicines and Healthcare products Regulatory Agency","year":"2021"},{"key":"2026012907423499500_ref84","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s0022-3476(75)80604-4","article-title":"The fetal hydantoin syndrome","volume":"87","author":"Hanson","year":"1975","journal-title":"J Pediatr"},{"key":"2026012907423499500_ref85","volume-title":"15q overgrowth syndrome | about the disease | GARD"},{"key":"2026012907423499500_ref86","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/tera.1420330314","article-title":"Fetal hydantoin effects","volume":"33","author":"Hanson","year":"1986","journal-title":"Birth Defects Res"},{"key":"2026012907423499500_ref87","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology."},{"key":"2026012907423499500_ref88","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1212\/01.WNL.0000044157.28073.DC","article-title":"Major malformations in offspring of women with epilepsy","volume":"60","author":"Kaaja","year":"2003","journal-title":"Neurology."},{"key":"2026012907423499500_ref89","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0920-1211(98)00084-9","article-title":"Congenital malformations due to antiepileptic drugs","volume":"33","author":"Kaneko","year":"1999","journal-title":"Epilepsy Res"},{"key":"2026012907423499500_ref90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Res"},{"key":"2026012907423499500_ref91","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register","volume":"77","author":"Morrow","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012907423499500_ref92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0022-3476(77)80421-6","article-title":"Are hydantoins (phenytoins) human teratogens?","volume":"90","author":"Shapiro","year":"1977","journal-title":"J Pediatr"},{"key":"2026012907423499500_ref93","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012907423499500_ref94","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"2026012907423499500_ref95","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jocn.2006.04.025","article-title":"Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences","volume":"14","author":"Vajda","year":"2007","journal-title":"J Clin Neurosci"},{"key":"2026012907423499500_ref96","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s0967-5868(03)00158-9","article-title":"The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months","volume":"10","author":"Vajda","year":"2003","journal-title":"J Clin Neurosci"},{"key":"2026012907423499500_ref97","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.seizure.2018.12.006","article-title":"Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register","volume":"65","author":"Vajda","year":"2019","journal-title":"Seizure."},{"key":"2026012907423499500_ref98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med"},{"key":"2026012907423499500_ref99","doi-asserted-by":"publisher","first-page":"CD010224","DOI":"10.1002\/14651858.CD010224.pub2","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"2017","author":"Weston","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012907423499500_ref100","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2017.12.102","article-title":"A systematic review of clozapine-induced myocarditis","volume":"259","author":"Bellissima","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026012907423499500_ref101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012907423499500_ref102","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.2459\/JCM.0000000000000379","article-title":"Role of biomarkers in monitoring antiblastic cardiotoxicity","volume":"17","author":"Novo","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"}],"container-title":["Toxicology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/15\/1\/tfaf184\/66630182\/tfaf184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/15\/1\/tfaf184\/66630182\/tfaf184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:43:09Z","timestamp":1769690589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxres\/article\/doi\/10.1093\/toxres\/tfaf184\/8444462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.1093\/toxres\/tfaf184","relation":{},"ISSN":["2045-4538"],"issn-type":[{"value":"2045-4538","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,29]]},"article-number":"tfaf184"}}